Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plant-based Empty Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plant-based Empty Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical and nutraceutical formulators, traditional gelatin capsules (derived from bovine or porcine collagen) are unsuitable for vegetarians, vegans, and individuals with religious dietary restrictions (Halal, Kosher) or allergies to animal proteins. Additionally, gelatin capsules have limited stability with certain fill materials (aldehydes, reducing sugars) and may cross-link, affecting dissolution. The plant-based empty capsule addresses this through vegetarian HPMC delivery: capsules made from hydroxypropyl methylcellulose (HPMC) and other edible plant polysaccharides, containing no animal-derived ingredients, offering excellent chemical stability, biocompatibility, and broad compatibility with sensitive fill materials. According to QYResearch’s updated model, the global market for Plant-based Empty Capsules was estimated to be worth US$ 573 million in 2025 and is projected to reach US$ 862 million, growing at a CAGR of 6.1% from 2026 to 2032. Plant-based empty capsules are hollow capsules primarily made from plant-derived materials, commonly hydroxypropyl methylcellulose (HPMC) and other edible plant polysaccharides. Unlike traditional gelatin capsules, plant-based empty capsules contain no animal-derived ingredients, making them suitable for vegetarians and individuals with allergies to animal proteins. They offer excellent chemical stability and biocompatibility, providing a safe delivery vehicle for pharmaceuticals, dietary supplements, probiotics, enzymes, and other functional ingredients. Due to their natural and controllable composition, these capsules are widely used in pharmaceutical, nutraceutical, and functional food applications, particularly for oral dosage forms that require specific release sites and dissolution profiles. In 2024, the global sales volume of plant-based empty capsules reached 173.1 billion capsules, with an average price of 31 USD per 10,000 capsules.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098130/plant-based-empty-capsules
1. Technical Architecture: Capsule Sizes and Material Properties
Plant-based empty capsules are segmented by size (capacity), determining fill volume and application:
| Capsule Size | Fill Volume (mL) | Typical Applications | Price per 10,000 capsules (USD) | Market Share (Units) |
|---|---|---|---|---|
| 00# | 0.91-0.95 | High-dose pharmaceuticals, probiotics (50B+ CFU) | $32-42 | 15% |
| 0# | 0.68-0.72 | Standard pharmaceuticals, nutraceuticals | $30-38 | 25% |
| 1# | 0.48-0.52 | Probiotics, enzymes, herbal extracts | $28-35 | 30% |
| 2# | 0.36-0.40 | Small-dose pharmaceuticals, pediatric formulations | $26-32 | 15% |
| 3# | 0.27-0.30 | Low-dose APIs, specialty applications | $24-30 | 10% |
| Others (4#, 5#, 0el) | 0.20-1.00 | Custom, veterinary, clinical trials | $22-45 | 5% |
Key technical challenge – moisture sensitivity and stability: HPMC capsules have lower equilibrium moisture content (3-7%) than gelatin (13-16%), making them suitable for moisture-sensitive fills. Over the past six months, several advancements have emerged:
- Lonza (February 2026) introduced a “low-moisture” HPMC capsule (Vcaps Plus) with <5% moisture content, ideal for hygroscopic APIs and probiotics (extending shelf life by 12 months).
- ACG Associated Capsules (March 2026) commercialized a “pullulan-based” plant capsule (plant-derived polysaccharide) with oxygen barrier 2x better than HPMC, protecting oxygen-sensitive probiotics (Lactobacillus, Bifidobacterium) for 24 months.
- Qualicaps (January 2026) launched a “gluten-free, non-GMO” HPMC capsule line targeting clean-label nutraceuticals, certified by third-party organizations (NSF, Non-GMO Project).
Industry insight – plant-based vs. gelatin capsule comparison:
| Parameter | Plant-based (HPMC) | Gelatin | Advantage |
|---|---|---|---|
| Source | Plant cellulose (wood pulp, cotton) | Bovine/porcine collagen | Vegetarian, vegan, Halal, Kosher |
| Moisture content | 3-7% | 13-16% | Better for moisture-sensitive fills |
| Cross-linking | None | Yes (with aldehydes, reducing sugars) | Compatible with wider range of fills |
| Dissolution (pH) | pH-independent (dissolves in water) | pH-independent | Similar |
| Temperature stability | Stable up to 60°C | Softens at 40°C | Better for tropical climates |
| Cost per 1,000 capsules | $2.80-4.20 | $2.00-3.20 | Gelatin cheaper (20-30%) |
2. Market Segmentation: Capsule Size and Application
The Plant-based Empty Capsules market is segmented as below:
Key Players: Qualicaps (US/Spain), Lonza (Switzerland/US), ACG Associated Capsules (India), Suheung (South Korea), CapsCanada (Canada), Sunil Healthcare (India), Evonik Specialty Chemicals (Germany), Shandong Healsee Capsule (China), Anhui Huangshan Capsule (China), Farmacapsulas (Colombia), Guangzhou Jiuzhou Capsule (China), Hunan Er-Kang Pharmaceutical (China), Hebei Kangxin Plant Capsule (China), Zhejiang Yueshan Capsule (China), Zhejiang Tianlong Capsule (China), Zhejiang Xinchang Kangping Capsule (China), Jiangsu Kangyoujian Biotechnology (China), Guizhou Guang De Li Pharmaceuticals (China), SUZHOU CAPSUGEL (China), Chongqing Heng Sheng Pharmaceutical (China), Jiangsu Youli Capsule (China), Jinan Gaohua Medicinal Capsule (China)
Segment by Capsule Size:
- 1# – Largest segment (30% of 2025 units). Most common for nutraceuticals (probiotics, enzymes, herbal extracts).
- 0# – 25% of units. Standard pharmaceutical capsules.
- 00# – 15% of units. High-dose products.
- 2# – 15% of units. Small-dose products.
- 3# – 10% of units. Low-dose specialty.
- Others – 5% of units.
Segment by Application:
- Pharmaceuticals – Largest segment (50% of revenue). Prescription drugs, OTC medications, clinical trial supplies.
- Health Supplements (Nutraceuticals) – 45% of revenue (fastest-growing, 8% CAGR). Vitamins, minerals, probiotics, enzymes, herbal supplements, fish oil.
- Others – Functional foods, veterinary (5% of revenue).
Typical user case – clean-label probiotic supplement: A nutraceutical brand launches a high-potency probiotic (50 billion CFU, 12 strains). Consumer concerns: animal-derived capsules (gelatin) conflict with “clean label” positioning. Plant-based HPMC capsules (Lonza Vcaps) used for “vegetarian” and “non-GMO” labeling. Cost premium: $0.002 per capsule ($0.02 per bottle). Value: attracts vegetarian/vegan consumers (20% of target market), supports premium pricing (+20%), and enhances brand image. Annual volume: 50 million capsules → $100,000 incremental cost → $500,000 incremental revenue.
Exclusive observation – “pullulan capsules” for oxygen-sensitive probiotics: Pullulan (polysaccharide from tapioca) has lower oxygen permeability than HPMC, extending probiotic viability (2-year shelf life vs. 18 months for HPMC). Pullulan capsules cost 20-30% more than HPMC but are preferred for high-potency, multi-strain probiotics. Pullulan segment growing at 10% CAGR.
3. Regional Dynamics and Vegetarian/Vegan Trends
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| Asia-Pacific | 45% | Largest capsule manufacturing base (China, India, South Korea), domestic manufacturers (Healsee, Huangshan, Jiuzhou, Er-Kang, Kangxin, Yueshan, Tianlong, Kangping, Kangyoujian, Guang De Li, Suzhou Capsugel, Heng Sheng, Youli, Gaohua), cost leadership |
| North America | 25% | Large nutraceutical market, vegetarian/vegan demand (10-15% of population), clean label movement |
| Europe | 20% | Strong pharmaceutical industry, vegetarian/vegan trends (Germany, UK), Lonza/Qualicaps/Evonik leadership |
| RoW | 10% | Emerging nutraceuticals (Latin America – Farmacapsulas, Middle East) |
Exclusive observation – “plant-based” market growth: Global plant-based food and supplement market grew 15% CAGR (2020-2025). Plant-based capsules benefit from this trend, with “vegetarian” and “vegan” labeling increasing consumer trust. Retailers (Whole Foods, Sprouts) preferentially stock plant-based capsules. Plant-based capsule penetration in nutraceuticals increased from 20% (2020) to 35% (2025), projected 50% by 2030.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global leaders | Lonza (Switzerland), Qualicaps (US/Spain), ACG (India), Suheung (Korea), CapsCanada (Canada), Evonik (Germany) | Full size range, enteric-coated options, global distribution, premium pricing (+20-30%) |
| 2 | Chinese domestic leaders | Shandong Healsee, Anhui Huangshan, Guangzhou Jiuzhou, Hunan Er-Kang, Hebei Kangxin, Zhejiang Yueshan, Zhejiang Tianlong, Zhejiang Kangping, Jiangsu Kangyoujian, Guizhou Guang De Li, Suzhou Capsugel, Chongqing Heng Sheng, Jiangsu Youli, Jinan Gaohua | Cost leadership (30-50% below global), domestic market dominance, export |
| 2 | Regional specialists | Farmacapsulas (Colombia), Sunil Healthcare (India) | Regional markets, cost-competitive |
Technology roadmap (2027-2030):
- Fermentation-derived cellulose capsules – Plant-based capsules from lab-grown cellulose (sustainable, no deforestation). Pilot stage.
- Edible coating integration – Taste-masking or delayed-release coatings integrated into capsule shell (no secondary coating).
- Plant-based capsules for liquid fills – HPMC capsules compatible with non-aqueous liquid fills (oils, PEG solutions), expanding application to softgel alternatives.
With 6.1% CAGR and 173.1 billion capsules sold in 2024, the plant-based empty capsule market benefits from vegetarian/vegan trends, clean label movement, and probiotic growth. Key growth drivers: animal-free formulation demand, moisture-sensitive API compatibility, and pharmaceutical shift toward plant-based excipients. Risks include higher cost vs. gelatin (20-30% premium), competition from gelatin (established, lower cost), and regulatory barriers (novel excipient approval in some markets).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
